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 Background: Malignant pleural mesothelioma is a rare lethal malignancy caused by asbestos exposure. It is more frequent-
ly seen in certain regions in Turkey. In this retrospective study, we aimed to analyse demographic, clinical, and 
pathological data and treatment-related features in 54 patients.
 Material/Methods: The study included 54 patients diagnosed with malignant mesothelioma that were followed and treated.
 Results: Of the 54 patients, 34 (55.6%) were male. The median age in men and women were 60.3 (38.2–77.2) and 65.8 
(37.7–77.5) years, respectively. In 35 (64.8%), exposure to asbestosis was present. Epithelial type was found 
in 27 (50.0%), followed by mixed type in 7 (13.0%) patients, and in 20 (37.0%) patients the subtype could not 
be determined. The disease was staged as IV in 37 (68.5%) patients. In 28 patients (51.9%), it was right-sid-
ed and in 1 (1.9%) it was bilateral. The most frequent metastatic sites (in decreasing order) were lungs, me-
diastinum, diaphragm, liver, and thoracal wall. Of the 54 patients, 36 (66.6%) received 1st-line chemotherapy 
and 20 (37%) 2nd-line chemotherapy. Eighteen patients (33.3%) received radiotherapy; 11 (20.3%) with palli-
ative intention and 7 (12.9%) with curative intention. Median overall survival (OS) was 12.03 months (95% CI 
7.2–16.8). OS was not affected by sex (p=0.32), smoking history (p=0.51), alcohol consumption (p=0.36), fami-
ly history (p=0.67), pleural effusion presence (p=0.80), operation (p=0.14), clinical stage (p=0.072), symptom at 
presentation (p=0.66), having mixed type histology (p=0.079), asbestos exposure (p=0.06), and type of 1st-line 
chemotherapy (p=0.161). On the contrary, it may be positively affected by good ECOG PS (0-1) (p<0.01), age 
below 65 (p=0.03), left-sided disease (p=0.01), receiving chemotherapy (p<0.01), having unilateral pleural ef-
fusion (p=0.018), and type of 2nd-line chemotherapy (p=0.025).
 Conclusions: OS of our patients was better than that found in the literature, seeming to be positively affected by early stag-
es, better ECOG PS, age below 65 years, left side involvement, and having second-line chemotherapy with cis-
platin-gemcitabine or 3M. Overall treatment success seems to be comparable to what is currently expected.
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Background
Malignant pleural mesothelioma (MPM) is an insidious can-
cer that emerges in pleura, peritoneal cavities, tunica vagi-
nalis, or on pericardial surfaces. Of the total cases, 80% are 
pleural. In 70% of the cases, a relationship with exposure 
to asbestos is detected. Other possible etiologic factors are 
radiotherapy, viral oncogenes, and genetic factors [1–3]. 
Mesothelioma is mainly seen in adults. It generally occurs 
in the 5th and 6th decades of the life and 70–80% of the pa-
tients are male. Most of these patients have a history of long-
term asbestos exposure during childhood [4]. The incidence 
of MPM in people without asbestos exposure is expected to 
be 1 in 1 million persons, whereas in people with exposure 
this ratio may be up to 10 in 100 persons [5]. Median over-
all survival ranges from 6 to 18 months. In patients with lo-
calized disease, survival can be increased by multimodality 
therapy [6]. Although extrapleural pneumonectomy is advo-
cated by some groups, pleurectomy and decortication is most 
widely utilized [7]. In advanced stages, combination chemo-
therapy of cisplatin and pemetrexed is the current standard 
[8]. Radiotherapy can be applied as a part of multimodali-
ty therapy for rather early stages and as a palliative tool at 
later stages [9].
The incidence of mesothelioma is decreasing in developed 
countries due to reduced exposure in working and living ar-
eas, but in underdeveloped and developing countries it is in-
creasing because of increased industrial and environmental ex-
posure [5,10]. In Western countries mesothelioma occurs as a 
result of environmental exposure in people living near asbes-
tos mines and through occupational exposure, but in coun-
tries such as Turkey, Cyprus, Greece, and Afghanistan it results 
from secondary contact with soil (white soil) mixed with asbes-
tos for domestic use [11–15]. In Turkey, the problem is main-
ly environmental and is an important public health problem 
in central and southeastern Anatolia. A study conducted by 
the Turkish Ministry of Health, Directorate of Cancer Control 
Department, in 8 Turkish cities of during 2004–2006, report-
ed that MPM was not among the 10 most common types of 
cancer in men and women, and its incidence in both sexes 
was below 1% [16].
As MPM is a rare disease, each study performed in large se-
ries of patients and published in the literature will advance the 
therapeutic approach to this disease. We think that sharing 
our experience about this disease, which is more commonly 
encountered in the neighboring cities compared to other re-
gions of our country, both by revealing its clinico-pathologi-
cal data and evaluating our therapeutic approaches and their 
outcomes, will make a substantial contribution to the med-
ical literature.
Material and Methods
Prior to study initiation, approval was obtained from the Başkent 
University ethics committee (Date and number: 20/09/2010-
KA10/133). In this retrospective study, we aimed to enroll pa-
tients treated at Adana Başkent Research and Training Hospital. 
The charts of 54 patients followed between January 2000 and 
June 2010 at Başkent University Medical Oncology Department 
were enrolled in this study. Key clinical parameters, disease, 
and therapies had been recorded in the electronic health re-
cords, including data on sex, age, smoking and drinking hab-
its, exposure to asbestosis, clinic stages, ECOG PS, disease ex-
tension, and treatment protocols).
The patients were generally diagnosed using VATS and pleu-
ral biopsy (25 with pleural biopsy, 7 with thoracotomy, 20 with 
VATS, and 2 with pleural fluid cytology). All patients had histo-
logical diagnosis, including hematoxylin-eosin and immunohis-
tochemistry for keratin, calretinin, EMA, mesothelin, CEA, and 
TTF-1. CT was used 25% of patients, MRI for 20% of patients, 
and PET CT for 55% of patients for initial staging. Operation 
decisions are taken in oncology tumor boards for patients suit-
able for operation and operation notes are also considered in 
our study. Only 5 of the patients with extrapulmonary pleurec-
tomy had lymph node sampling; all other patients’ lymph node 
status was considered and compared with PET CT.
All patients were followed and screened with computerized 
tomography at 3-month intervals, in line with general follow-
up protocols of the medical oncology department.
Statistical	analysis
Statistical analysis was performed by using SPSS 15.0 soft-
ware. For all data, frequency, mean, and standard deviation 
were calculated. Survival was analyzed by Kaplan-Meier meth-
od and factors that might have an effect on the survival were 
examined using the log-rank Test. Statistical data were con-
sidered to be significant at p<0.05.
Results
A total of 54 patients, of whom 30 (55.6%) were male, were 
enrolled in the study. Demographic and clinical characteristics 
features of patients are given in Table 1.
At the time of diagnosis, 22 patients were found to have non-
pleural metastasis. Of the patients, 22 had palliative or cura-
tive operations (16 patients had pleurectomy/decortication, 
5 patients had extrapleural pneumonectomy, and 1 patient 
had pleurodesis). No mortality was seen in patients with sur-
gical operation. Five of them had postoperative complication 
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Characteristic N=54 %
Gender Male 30 55.6
Female 24 44.4
Age Male 60.3 38.2–77.2*
Female 65.8 37.7–79.5*
Classification by the age of 65 <65 32 59.3
≥65 22 40.7
Asbestos exposure Yes 35 64.8
No 9 16.7
Unknown 10 18.5
Smoking Yes 22 40.7
No 32 59.3
Ecog ps* at the time of diagnosis 0 4 7.4
1 30 55.6
2 17 31.5
3 3 5.6
Histological type Epithelial 27 50.0
Sarcomatoid 0 0.0
Mixed 7 13.0
Undefined 20 37.0
Pathological stage 2 2 3.7
3 15 27.8
4 37 68.5
Clinical stage 2 5 9.2
3 16 29.6
4 33 61.2
Presenting symptom Shortness of breath 23 42.6
Shortness of breath + chest pain 23 42.6
Shortness of breath + effusion 8 14.8
Side of involvement Right 28 51.9
Left 25 46.2
Bilateral 1 1.9
Pleural effusion Yes 46 85.2
No 8 14.8
Pleural effusion Unilateral 45 83.3
Bilateral 1 1.9
Table 1. Demographic and clinical characteristics of the patients.
ECOG-PS – Eastern Cooperative Oncology Group-performance status; * 95% Confidence interval (CI).
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(e.g., empyema, bleeding). Mean hospitalization of patients 
who had surgery was 8.1 days.
Only 1 patient was treated with neoadjuvant therapy. In the 
first-line treatment, 36 patients received a total of 176 cy-
cles of therapy (median 5.1) and the most common adverse 
effects were anemia (13.8%, grade I–II), neutropenia (13.8%, 
grade I–III), nausea and vomiting (10.2%, grade II), and throm-
bosis and asthenia (2%). In the second-line treatment, 20 pa-
tients received a total of 75 cycles of therapy (median 3.75) 
and common adverse effects were neutropenia (25%, grade 
I–IV), thrombocytopenia (10%, grade II–III), anemia (grade I–II), 
and neuropathy (5%). The therapies given to the patients are 
shown in Table 2.
Overall survival data and their relation with other factors are 
shown in Table 3. Kaplan-Meier curve for overall survival is given 
in Figure 1. An insignificant correlation was observed between 
sex and overall survival (12.03, 95% CI: 7.24–16.83) (Figure 2).
A statistically significant difference was found between overall 
survival and age above or below 65, ECOG PS status 0–1 or >1, 
second-line treatment with cisplatin-gemcitabine or cisplatin-
pemetrexed, 1-sided or 2-sided pleural effusion with, site of in-
volvement left or right side, and taking chemotherapy or not.
Median progression-free survival was 7.33±0.87 (95% CI: 
5.61–9.05) months. No statistically significant correlation was 
found between sex and receiving chemotherapy and progres-
sion-free survival (Table 4).
Discussion
MPM is a rare, insidious type of cancer. Progress in its treat-
ment has been slow. This disease is also an important health 
problem in Turkey. Asbestos exposure is still a problem in 
developing countries such as Turkey. In this study, at one of 
the most comprehensive oncology centers of the region, we 
studied the patients who were treated at our hospital.
Of 54 patients enrolled to our study, 30 were male and 24 
were female. We found that, in line with the published liter-
ature, the disease seems to be more common in men, proba-
bly because of higher levels of occupational and environmen-
tal exposure to asbestos, as in other countries [14,17,18]. In 
our study, the M/F ratio was 1.25. Among our patients, mean 
age was calculated to be slightly lower in men compared to 
women, which may be because men are exposed to asbestos 
most intensely and at an earlier age [13,19].
The disease initiation period after asbestos exposure is not ex-
actly known, but the mean period was calculated as 32 years 
in 1 study [20]. Of the patients, 35 (64.8%) were definitively 
exposed to asbestos for at least a part of their lives and only 
9 (18.5%) had no history of exposure to asbestos. Thirty-six 
patients were born in the regions of Turkey in which the ex-
posure to asbestos is high and, although they immigrated to 
other regions after spending an average of 20–30 (mean 23.4 
years) years in high-risk regions, they could not escape from 
malignant mesothelioma after the 6th decade of life. This is 
especially important for showing that in some places of our 
country, there is a high level of asbestos exposure (men who 
work in marble and stone quarries where there are high lev-
els of asbestos exposure and women who paint their house 
annually with asbestos-containing lime) [21]. When we eval-
uated our patients for other additional factors, we found that 
40% smoked and only 1.9% consumed alcohol. Previous ad-
ministration of radiotherapy, which is an etiological risk factor 
for malignant mesothelioma, was not reported in any patient. 
The fact that nearly all of our female patients are house-
wives suggests that, in our country, in this group, painting 
the house with asbestos-containing lime paint rather than in-
dustrial or occupational exposure is the leading type risk [22]. 
Treatment Type N, (%)
First-line CT* (N=36) Cisplatin-pemetrexed  24 (44.4)
Cisplatin-gemsitabine  2 (3.7)
3M***  10 (18.5)
Second-line CT (N=20) Cisplatin-pemetrexed  5 (9.2)
Cisplatin-gemsitabine  12 (22.2)
3M***  3 (5.5)
RT** (N=18) Palliative  11 (20.4)
Curative  7 (13.0)
Table 2. Treatment modalities initiated to the patients.
* CT – chemotherapy; ** RT – radiotherapy; ***3M – mitoxantrone, methotrexate, mitomycine-c.
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Interestingly, only 1 of the patients had a familial history of 
malignant mesothelioma.
In MPM, age (below vs. above 65 years) is an important fac-
tor affecting prognosis [23]. Aggressive treatment is suggested 
for patients under age 65, even if there are additional risk fac-
tors [24]. In our patient group, overall survival was significant-
ly higher in the patients below age 65 compared to those over 
65 (15.8 and 9.2 months, p=0.037). Another factor that shows a 
good prognosis is the performance status of the patient at the 
Parameters Median (95% CI, months) P
Survival Overall  12.03 (7.2–16.8)
Gender Male  11.38 (9.0–13.7)
0.32
Female  16.51 (7.4–25.5)
Age <65  15.88 (13.3–18.4)
0.03
≥65  9.27 (5.1–13.4)
Smoking Yes  17.69 (5.5–29.8)
0.51
No  12.03 (7.6–16.4)
ECOG-PS* O–1  15.88 (7.7–24.0)
<0.01
>1  9.93 (4.3–15.5)
Clinical stage 2  10.95 (0.0–31.7)
0.073  18.58 (8.4–28.7)
4  11.38 (8.0–14.7)
Histological type Epithelial  12.00 (4.9–19.0)
0.07
Mixed  17.69 (5.0–30.3)
Site of involvement Right  10.95 (8.4–13.4)
0.01Left  18.58 (6.1–31.0)
Bilateral  1.480
Pleural effusion Yes  12.03 (5.1–18.9)
0.80
No  11.38 (5.1–17.6)
Pleural effusion Bilateral  1.480
0.01
Unilateral  12.03 (5.2–18.8)
Operation Yes  16.51 (11.2–21.7)
0.14
No  9.93 (5.9–13.9)
Chemotherapy Yes  17.69 (13.0–22.3)
<0.01
No  2.82 (0.0–7.8)
1st line treatments Cisplatin/pemetrexed  18.94 (7.8–30.0)
0.16
3M**  16.51 (10.0–23.0)
2nd line treatments Cisplatin/pemetrexed  12.00 (6.4–17.5)
0.02Cisplatin/gemzar  18.94 (15.3–22.5)
3M  44.35 (16.4–72.2)
Table 3. Overall survival data and their relation with other clinical factors.
* ECOG-PS – Eastern Cooperative Oncology Group-Performance status; ** 3M – mitoxantrone, methotrexate, mitomycine-c.
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time of diagnosis [23]. As expected in the patients with a perfor-
mance status of 0–1 at the time of diagnosis, overall survival is 
better. In our study, 34 patients (62.9%) had a performance sta-
tus of 0–1 at the time of diagnosis and a better overall survival 
was calculated compared to the patients with ECOG performance 
>1 (p<0.01). Life expectancy is longer in the patients with earli-
er clinical and pathological stage [23]. In our study, the patients 
with stage III disease had longer lifespan compared to those with 
stage II or stage IV diseases (18.5 months, 10.9 months, and 11.3 
months, respectively). This difference may be explained by the 
fact that the patients have other risk factors (e.g., histology, age, 
ECOG PS). Reports in the general literature suggest aggressive 
therapies will not contribute to overall survival, patients with ep-
ithelial histology have a better prognosis, and aggressive thera-
py may not be suitable in patients with non-epithelial histology 
[24,25]. In our patient group, the patients with mixed histology 
had surprisingly prolonged survival compared to those with ep-
ithelial histology (17.6 months and 12.0 months, respectively, 
p=0.079). This result, which differs from results in the general lit-
erature, may be due to the lack of histopathologic subgroup de-
scription in 20 patients in our series, which might have changed 
the statistical results. Difficulties in the diagnosis of malignant 
mesothelioma should be kept in mind [26].
At the time of diagnosis, the most commonly reported com-
plaints were shortness of breath and chest pain [27]. Although 
the presence of chest pain at the time of admission was re-
ported to be a good prognostic factor [23], no significant cor-
relation could be detected between the presenting symptom 
and overall survival (p=0.661). In more than one-third of pa-
tients, there is pleural effusion-related shortness of breath 
without chest pain [28]. In the patients with pleural fluid, cy-
tological examination may demonstrate malignant cells in one-
third of the cases [4]. In our case series, 85.2% of the patients 
were reported to have pleural effusion at the time of diagno-
sis and all but 1 had unilateral effusion. Although the major-
ity of the patients have pleural effusion, in our clinic, only 2 
patients had the diagnosis using pleural cytology. Histological 
subgroup classification of mesothelioma may not be performed 
using other closed biopsy methods such as pleural cytology 
[29]. However, biopsy using VATS and open thoracotomy is 
more likely to lead to a diagnosis [30]. In our study, 44.4% of 
the patients were diagnosed by VATS and open thoracotomy 
surgery. Inadequate biopsy material is a problem in our study 
and inability to perform subgroup analysis in the majority of 
the patients may be caused by this factor.
Characteristic Median (95% CI; months) P
General  7.66 (4.7–10.5)
Gender Male  7.33 (3.6–10.9)
0.314
Female  7.76 (2.7–12.7)
Chemotherapy Yes  7.76 (3.6–11.8)
0.572
No  6.57 (1.3–11.8)
Table 4. Progression-free survival after firstline chemotherapy.
Figure 1. Overall survival curve for all patients (n: 54).
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Figure 2. Overall survival curve according to gender (p=0.32).
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For the treatment of MPM, 3 important surgical procedures 
were defined: surgical pleurodesis, P/D, and EPP with VATS 
[25,31,32]. In the surgical procedures, mortality is less than 
5% [31]. In our study, 22 patients underwent surgery (9 pleu-
rectomy, 1 pleurodesis, 5 EPP, and 7 P/D) and no mortality 
occurred. Despite the substantial potential for morbidity, sur-
gery may be beneficial in the palpation of the major symp-
toms such as resection pain and dyspnea [33]. Reports on the 
effect of P/D on overall survival are contradictory. Based on 
some data, VATS + P/D may be beneficial to ensure the sur-
vival benefit in the patients who are not candidates for EPP 
[34]. Despite the high morbidity (60%) and mortality (4–9%) 
observed with EPP, when administered along with chemo-
therapy and radiotherapy, this procedure may allow use of 
higher doses of radiotherapy, as well as prolonging surviv-
al in the presence of local recurrence and early disease [35]. 
However, EPP alone does not seem to prolong life expectan-
cy [24]. In our study, there was not difference of overall sur-
vival between the patients who underwent surgery and those 
who did not undergo surgery. In Turkey most patients are di-
agnosed at an advanced stage, so there is scant opportuni-
ty to initiate trimodal therapy. A study considering trimod-
al therapy in stage 1–3 MPM patients revealed that median 
overall survival is approximately 16.8 months after neoadju-
vant treatment with cisplatin-pemetrexed and following EPP 
and radiotherapy [36].
Although local control of the patients is ensured using surgery 
and radiotherapy, many patients develop systemic metasta-
sis. Chemotherapy leads to prolonged life expectancy and im-
proved quality of life and relieves the symptoms. The response 
rates obtained with chemotherapy ranged between 0% and 
45% [37]. A phase 2 study reported by Nowak et al. revealed 
that median overall survival was 11.2 months with cisplatin-
gemcitabine therapy [38]. In our study, overall survival time 
was found to be significantly longer in the patients treated 
with chemotherapy compared to those who did not receive it 
(17.6 months and 2.8 months, respectively, p<0.001). In the 
first-line treatment, we administered cisplatin-pemetrexed, 
cisplatin-gemcitabine and 3M (mitoxantrone, methotrexate, 
mitomycin-c) protocols and we did not find a difference in 
survival times among these 3 groups (p=0.161). In the sec-
ond-line treatment, both the patients who received cisplatin-
gemcitabine and those who received 3M protocols showed a 
significant difference of survival in second-line therapy com-
pared with best supportive care (p=0.025). In the analyses of 
progression-free survival of the patients, the contribution of 
the chemotherapy did not show a significant difference be-
tween sexes.
Conclusions and Recommendations
1.  MPM patients have a poor life expectancy, with a mean sur-
vival of approximately 1 year after diagnosis.
2.  Because exposure to asbestos is the main etiological factor 
in 80% of the cases, primary prevention should be the first 
goal, especially in developing countries.
3.  Selection of the potentially most appropriate surgical meth-
od in the patients who were diagnosed allows at least con-
trolling the symptoms.
4.  In the patients with early-stage disease, triple therapy (sur-
gery, radiotherapy, and chemotherapy) options may be tried.
5.  In the patients with advanced-stage disease, in light of 
many studies that showed significant survival differences 
by the best supportive therapy, we recommend giving at 
least first-line therapies to all patients with an appropriate 
performance status.
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